Shire (LON:SHP)‘s stock had its “buy” rating restated by equities researchers at Societe Generale in a research report issued to clients and investors on Monday. They currently have a GBX 8,000 ($108.49) price target on the biopharmaceutical company’s stock. Societe Generale’s target price indicates a potential upside of 131.95% from the company’s previous close.
Several other equities analysts have also recently weighed in on SHP. Liberum Capital reiterated a “buy” rating and issued a GBX 4,200 ($56.96) price objective on shares of Shire in a research note on Monday, November 20th. Barclays reiterated an “equal weight” rating on shares of Shire in a research note on Monday, January 22nd. Kepler Capital Markets reiterated a “buy” rating and issued a GBX 4,600 ($62.38) price objective on shares of Shire in a research note on Wednesday, November 1st. BNP Paribas reiterated an “outperform” rating and issued a GBX 4,700 ($63.74) price objective on shares of Shire in a research note on Tuesday, January 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating on shares of Shire in a research note on Friday, November 17th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of GBX 5,082.35 ($68.92).
Shire (LON SHP) opened at GBX 3,449 ($46.77) on Monday. Shire has a one year low of GBX 3,341.50 ($45.31) and a one year high of GBX 5,067 ($68.71). The firm has a market cap of $31,150.00 and a P/E ratio of 2,759.20.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.